KRAS and non-small cell lung carcinoma: To identify the critical eIF4A-regulated targets that, when suppressed, sensitize NSCLCs to KRAS G12C or MEK inhibitors, we performed a screen to interrogate 14 established, direct eIF4A translational targets and downstream signaling pathways in response to eFT226 (eIF4Ai) in 2 different sensitive NSCLC lines, eliminating the few targets that would not be expected to exert cell-autonomous effects (e.g., MMPs, PD-L1).